Saturday 17 October 2026
Export BMRA’s income statement to Excel — free account
Biomerica, Inc.
BMRA Healthcare Medical Devices
Biomerica, Inc.’s revenue for fiscal 2026 (year ended May 2026) was $4.5 million, down 16.2% from fiscal 2025. In the quarter to May 2026, revenue grew 17.0%, EPS grew 37.8% and free cash flow fell 35.1%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
1.85
0.03
−1.60%
Follow BMRA
| Older periods | Aug '25 | Nov '25 | Feb '26 | May '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
1.62 | 1.47 | 1.41 | 1.54 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(29.54) | (6.63) | (4.89) | (7.54) | |
P/B ratio |
1.54 | 1.48 | 1.84 | 2.62 | |
Price to Tangible BV |
1.61 | 1.56 | 1.98 | 2.84 | |
EV/Sales |
1.00 | 0.90 | 1.10 | 1.25 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(1.76) | (1.36) | (1.51) | (1.63) | |
EV/FCF |
(1.70) | (1.32) | (1.46) | (1.60) | |
Quick Ratio |
2.52 | 2.18 | 1.46 | 0.84 | |
Current Ratio |
3.48 | 3.25 | 2.64 | 1.62 | |
Net Debt/EBITDA |
3.00 | 2.00 | 1.12 | 0.92 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.66 | 0.67 | 0.71 | 0.70 | |
Operating CF/Net income |
(134.00) | 0.75 | 0.95 | 0.80 | |
Capex/Depreciation |
0.00 | 0.00 | (0.18) | 0.16 | |
Research and Development Expense of Revenue |
15.36% | 15.95% | 18.03% | 23.40% | |
Selling, General and Administrative Expense of Revenue |
96.38% | 101.74% | 109.02% | 143.49% | |
Intangible Assets out of Total Assets |
0.03 | 0.04 | 0.05 | 0.03 | |
Share Based Compensation of Revenue |
9.64% | 9.67% | 13.68% | 10.39% | |
Graham Net Nets |
0.53 | 0.55 | 0.42 | (0.02) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(52.32%) | (68.12%) | (73.87%) | (53.78%) | |
Free Cash Flow Yield |
(36.05%) | (46.47%) | (53.64%) | (50.54%) | |
Revenue per Share |
0.52 | 0.42 | 0.33 | 0.30 | |
Operating CF per Share |
(0.10) | (0.34) | (0.42) | (0.31) | |
Capex per Share |
0.00 | 0.00 | (0.01) | 0.01 | |
Free Cash Flow per Share |
(0.10) | (0.34) | (0.42) | (0.31) | |
Cash per Share |
1.16 | 0.87 | 0.44 | 0.45 | |
Shareholders Equity per Share |
1.95 | 1.53 | 1.10 | 0.90 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.95 | 1.53 | 1.10 | 0.90 | |
Free Cash Flow |
(0.27) | (0.99) | (1.27) | (0.89) | |
Working Capital |
4.21 | 3.59 | 2.56 | 1.54 | |
Capital Expenditures |
— | — | (0.02) | 0.02 | |
Net Current Asset Value |
4.20 | 3.59 | 2.56 | (0.11) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.02 | (0.02) | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
1.38 | 1.14 | 1.10 | 0.76 | |
Average Payables |
0.89 | 0.79 | 0.68 | 0.92 | |
Average Inventory |
1.71 | 1.66 | 1.65 | 1.60 | |
Average Assets |
7.36 | 6.65 | 6.13 | 6.35 | |
Average Common Equity |
5.25 | 4.77 | 4.43 | 3.37 |
Columns are period end dates